+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 1Month - 5Years
All Genders
ID06525584

Evaluating Ketamine Infusion for Brain Protection After Heart Surgery in Children with Congenital Defects

Led by Kemerovo State Medical University · Updated on 2026-08-17

196

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of ketamine infusion in subanesthetic doses as a neuroprotective method during the postoperative period in children undergoing surgery to correct congenital heart defects involving atrial or ventricular septal defects. The study aims to assess the safety and effectiveness of this approach in preventing brain injuries after these surgeries performed with cardiopulmonary bypass. Participants are randomly assigned to receive either ketamine infusion at doses of 0.1 mgkghour or 0.3 mgkghour for 16 hours, or no ketamine control group after their surgery. This intervention period focuses on the immediate postoperative phase to monitor ketamines impact on neuroprotection. During the study, children will undergo evaluations including biomarker measurements 16 hours after surgery to assess brain injury markers. Researchers will monitor safety and neuroprotective outcomes while following participants until study completion. The total participation duration aligns with the postoperative assessment period and study endpoints.

CONDITIONS

Brief Title

Ketamine Infusion as a Method of Cerebral Protection in Children

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here